Introduction
The venom of the honey bee Apis mellifera (L.) is a complex mixture of pharmacologically and biochemically active agents. Investigations into the composition of the venom were first reported by Langer (1897) and more recently it has been shown by Neumann & Habermann (1954) that most of the biological activity was due to the peptides and proteins in the venom.
The components of the venom can be separated by dialysis into two fractions. The Habermann & Reiz (1965b) and the major constituents have now been purified.
Three basic low molecular weight peptides have been described. Melittin, by weight the principal constituent of the venom (c. 30%) is a peptide of 26 amino acid residues, which has a high surface activity and is a potent haemolysin (Habermann & Jentsch, 1966) . Apamin (c. 2% of the venom) contains 18 amino acid residues and is a neurotoxin producing motor abnormalities associated with actions upon the central nervous system (Habermann & Reiz, 1 965a). The third peptide (c. 1% of the venom), first isolated by Breithaupt & Habermann (1968) , contains 22 amino acid residues and was described as a mast cell degranulating (MCD)-peptide. The primary sequence of this peptide was reported by Haux (1969) and is in agreement with that found by Vernon, Hanson & Brimblecombe (1969) , who also determined the position of the two disulphide bridges in the peptide which they called 401 (Figure 1 ). Billingham, Morley, Hanson, Shipolini & Vernon (1973) observed that the peptide showed marked antiinflammatory activity in the rat against carrageenin-induced oedema and that it suppressed developing and established adjuvant arthritis.
The present study has confirmed the antiinflammatory property of this peptide and has attempted to establish its mechanism of action. A preliminary account of this work was presented to the Society (Hanson, Morley & Soria-Herrera, 1972) .
Methods

Iodination
Rat serum albumin was labelled with 125I by the iodine monochloride method (Macfarlane, 1958) . The labelled albumin was separated from unbound iodine by column chromatography (G 10 Sephadex). Aliquots were stored at -200 C.
Inflammatory stimuli
Joint oedema was provoked by injection of 0.01 ml turpentine oil into the synovial cavity of the right knee joint with a micrometer syringe (AGLA, Burroughs Wellcome). Carrageenin oedema was provoked by sub-plantar injection of 0.1 ml of a solution of carrageenin (1% in 0.9% w/v NaCl solution) into the right hind foot. In all experiments the contralateral uninjected site was used as the control, the responses being expressed as a paired difference. Intradermal injections were made in a volume of 0.1 ml into abdominal flank skin.
Vascular permeability measurements
Wistar strain rats (150-250g) received an intravenous injection of 0.5 ml of 125 I-labelled rat serum albumin (c. 10 ,Ci/mg, 2.5 mg/ml) mixed with Evans blue dye (2%). Injection was via the sublingual vein under light ether anaesthesia. Immediately following this intravenous injection, the appropriate inflammatory agent was injected. Anti-inflammatory agents were administered by intraperitoneal, subcutaneous or intravenous injection either at the same time as, or at appropriate periods before the application of the inflammatory agent and the isotope injection. After an interval of 1 h for skin tests and 4 h for joint or foot lesions, rats were anaesthetized and 1 ml samples Fig. 1 (1963) .
Results
Effect of 401 on turpentine and carrageenin oedema
Intra-articular injection of 0.01 ml of turpentine in the rat causes a severe inflammatory response with an initial oedematous phase occurring in the first few hours. In this oedematous phase, the increase in vascular permeability of the synovial and neighbouring vessels gave a substantial accumulation of extravascular albumin. The time course of this accumulation was determined by giving an intravenous injection of 125 I-albumin to animals at 0, 1, 2, 3 and 5 h after intra-articular turpentine injection and measuring the extravasated albumin 1 h later ( Figure 2a ).
Subplantar injection of carrageenin in the hind foot of the rat also causes a severe oedema and the time course of this accumulation of extravascular albumin was determined in a similar manner ( Figure 2b ). Turpentine oedema was also assessed by measuring the joint swelling with a gauge and in carrageenin oedema the paw volume was measured by weighing the hind feet. Figure 2 shows that the results obtained by these methods were comparable and that isotope accumulation provided a sensitive method for measurement of these inflammatory reactions. The measurements of isotope accumulation show that the response is biphasic in both tests and that a period of 4 h includes both phases of the response. Accordingly in both test systems an intravenous pulse of 1 5I-albumin of 4 h duration was used to measure the inflammatory reaction. Peptide 401 given subcutaneously immediately before intra-articular turpentine injection suppressed the oedema in a dose-related manner with a maximal effect at c. 1 mg/kg (Figure 3a ). This dose reduced albumin accumulation by about 85%. There was a similar suppression of the inflammatory response caused by subplantar injection of carrageenin and a 80% reduction in albumin accumulation was obtained with a dose of 1 mg/kg (Figure 3b ).
In these experiments, the inflammatory response was calculated as the increase in 125 albumin content of the injected site (knee or foot) over that observed for the contralateral uninjected site. Thus an agent causing an increase in the 125I-albumin content of the uninjected site (e.g. by systemic inflammatory action) might cause an increases vascular permeability as would be expected from its potency as a mast cell degranulating agent (Breithaupt & Habermann, 1968) . It produces increased vascular permeability following intradermal injection in both the rat and the guinea-pig. The inflammatory dose-response relationships (10 ng-100 /ug/ml) are shown in Figures   5a and b. Since the local concentration occurring on subcutaneous injection of 401 in antiinflammatory studies exceeded these doses, the possibility existed that the anti-inflammatory activity of 401 might in some way be associated with its own local inflammatory actions. Melittin, another peptide from bee venom which also causes mast cell degranulation, hypotension (Table 2 ) and increased vascular permeability (Fig. 5a) , and the potent mast cell degranulating synthetic compound 48/80 (Table 2) were therefore compared with 401 for their ability to suppress increased vascular permeability. Melittin (2 mg/kg) showed no significant inhibition of turpentine oedema nor did it reduce responses evoked by intradermal injection of histamine, 5-HT or bradykinin. In contrast, comparable doses of 401 caused marked (Breithaupt & Habermann, 1968 Figure Sb) . Pretreatment of the rat with the specific antagonists, mepyramine maleate (2.5 mg/kg) and methysergide bimaleate (2.5 mg/kg) fully suppressed skin reactions to histamine (0.5 mg) and 5-HT (0.2 mg) but not bradykinin (0.3 Mg) and caused only slight reduction of responses to intra-articular turpentine or subplantar carrageenin. This pretreatment had little effect on the ability of peptide 401 to reduce the inflammatory response to subplantar carrageenin (Figure 3 ). In these 401-treated animals the use of mepyramine and methysergide caused a reduction in the count of both injected and uninjected feet (Fig. 6) , an effect presumably due to antagonism of systemically released histamine and 5-HT. Whilst this pretreatment was without effect on the antiinflammatory action of 401, it did cause some reduction in the anti-inflammatory activity of 48/80. Because of its potent mast cell degranulating action, 401 is relatively toxic on intravenous injection. However, pretreatment with mepyramine and methysergide permitted intravenous administration of 401 and in such experiments the anti-inflammatory potency of 401 was comparable with that observed following subcutaneous injection (Figure 3 ).
(2) Specificity of action. The inflammatory responses in the rat to intra-articular injection of turpentine and subplantar carrageenin are complex, possibly involving sequential release of a number of endogenous agents (Di Rosa, Giroud & Willoughby, 1971) . Drugs which increased the calibre and permeability of blood vessels by direct action on the vascular wall were therefore used. Peptide 401 at a dose of 1 mg/kg injected subcutaneously totally abolished dye accumulation following intradermal injection of bradykinin (0.2 pg), prostaglandin E1 (0.5 Mg), serum kallikrein (100 Ag), histamine (0. (Florey, 1962) and thereby activated endogenous anti-inflammatory mechanisms, particularly the sympathetic and adrenal systems. However, pretreatment of the animals with mepyramine and methysergide prevented the increased vascular permeability on subcutaneous injection of 401 without substantially affecting its antiinflammatory activity. The possible contribution of neural mechanisms to the anti-inflammatory activity was investigated by studying the effect of 401 on turpentine oedema in denervated limbs. This treatment had no significant effect on the anti-inflammatory action of 401 (Figure 7 ). Pretreatment of the animals with phenoxybenzamine (10 Mg/kg) an agent which specifically blocks a-adrenoceptors, also had little effect on the anti-inflammatory activity of 401 ( Figure 7 ). The effect of 401 on turpentine oedema was also measured in adrenalectomized animals six and nine days after operation. Although there was some reduction of the anti-inflammatory activity of 401 (Fig. 7) it is clear that the release of adrenal cortico-steroids cannot account for a large part of this anti-inflammatory action.
The release of prostaglandin F20a was considered as a possible mechanism in view of its reported anti-inflammatory action in this species (Willoughby, 1968) . However, in doses up to 50 Mug/kg any apparent anti-inflammatory action of prostaglandin F2CI could be accounted for by the increased count in the contralateral knee. These experiments show that the anti-inflammatory action of 401 cannot merely be attributed to the stimulation of adrenergic or corticosteroid factors or release of prostaglandin F2a-(4) Vasomotor activity. Subcutaneous injection of 401 at a dose level at which anti-inflammatory activity is maximal in turpentine arthritis and carrageenin oedema resulted in a sustained fall in blood pressure apparent after 1 h and persisting for several hours (Figure 8 ). This hypotensive response is reduced by pretreatment with mepyramine (2.5 mg/kg) and methysergide (2.5 mg/kg) which allows intravenous injection of 401. This pretreatment does not affect the anti-inflammatory activity of 401 (Fig. 3) , 1971) . In addition to these actions, peptide 401 suppresses the development of adjuvant arthritis and reduces the severity of primary and secondary lesions in established adjuvant arthritis (Billingham et al., 1973) . In addition to its anti-inflammatory action, 401 is a potent mast cell degranulating agent in vivo subcutaneous injection of 401 (2 mg/kg) in restrained rat. (b) and in vitro and this property could account for the hypotensive and vascular permeability effects observed on intravenous or subcutaneous injection. However, it is not possible to attribute the anti-inflammatory action of 401 merely to vasoactive amine release following mast cell degranulation since other mast cell degranulating agents with a different (e.g. melittin) or similar (e.g. 48/80) mechanism of action (Breithaupt & Habermann, 1968) do not exhibit comparable antiinflammatory activity in the tests employed in this investigation. Also, pretreatment of rats with mepyramine and methysergide to antagonize the actions of histamine and 5-HT reduced the systemic hypotension and abolished the local inflammation produced by 401 without loss of antiinflammatory activity; the slight reduction in anti-inflammatory activity against carrageenin and turpentine oedema being consistent with specific antagonism of histamine and 5-HT release in these inflammatory reactions. 401 is without antiinflammatory action in guinea-pigs, although it causes increased vascular permeability on intradermal or subcutaneous injection. It is therefore unlikely that the anti-inflammatory action of 401 depends upon its irritant properties. Nonetheless, it remains possible that the anti-inflammatory property of 401 may be in some way related to mast cell degranulation or other tissue damage since large doses of prostaglandin El (1 mg/day) reduce the severity of adjuvant arthritis (Zurier & Ballas, 1973) and alkylpseudothioureas reduce inflammatory reactions to a wide range of stimuli (Ercoli, Arbona & Tabernero, 1971) .
The lack of specificity of action of 401 and more especially its ability to suppress responses to intradermal injection of smooth muscle spasmogens, indicate that 401 does not depend upon depletion of substrates (e.g. kininogen, complement) for its mode of action. Whilst adrenalectomy caused some reduction in the potency of 401, denervation and pretreatment with phenoxybenzamine had little effect. It can be concluded, therefore, that alterations in cortico-steroid release or vasomotor activity can only make minor contributions to the anti-inflammatory action of 401. A modification of prostaglandin synthesis has not been excluded, although for such a mechanism of action to operate, it is necessary to presuppose that skin reactions to histamine, bradykinin and 5-HT depend upon coincident prostaglandin synthesis, at present an unlikely assumption in view of the inability of non-steroidal antiinflammatory drugs to suppress all of these responses in rats (see Collier, 1969 
